AI news impact · US stocks
Eli Lilly and Company (LLY) news impact
On 2026-11-18 Wave Radar's AI rated the news on Eli Lilly and Company as neutral (impact score +25%).
Barclays raised Eli Lilly's price target to $1,550 on 39% Q3 revenue growth, and Lilly participated in VitriVax's $87M round; a vendor suffered a breach, but Lilly's internal systems were safe.
- Direction
- Neutral
- Impact score
- +25%
- Confidence
- 80%
- Headlines read
- 5
- Date
- 2026-11-18
AI assessment
Lilly's growth outlook remains intact with bullish analyst revisions and pipeline investments, while the third-party breach appears contained without internal intrusion.
Sector impact
Lilly's continued revenue strength and pipeline investments maintain positive sentiment across the large-cap pharmaceuticals and biopharma landscape.
Headlines the AI read
- VitriVax Announces $87 Million Series C Financing to Advance Lyme Disease Vaccine Candidate into the Clinic and Expand Pipeline Yahoo Finance/LLY · 2026-11-18
- Eli Lilly Is Up 39% in a Year. Barclays Sees Another 9% Yahoo Finance/LLY · 2026-11-17
- Coca-Cola Stock (KO) May Struggle to Repeat Its Strong 2026 Performance Yahoo Finance/LLY · 2026-11-17
- Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027? Yahoo Finance/LLY · 2026-11-17
- Third-Party Vendor Linked to Eli Lilly Is Hit by Data Breach Yahoo Finance/LLY · 2026-11-17
Rating history
One rating per trading day the stock was covered.
More on Eli Lilly and Company
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.